Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Review Article

Can Nanomedicinal Approaches Provide an Edge to the Efficacy of Tyrosine Kinase Inhibitors?

Author(s): Sunaina Indermun, Pradeep Kumar, Mershen Govender and Yahya E. Choonara*

Volume 30, Issue 13, 2023

Published on: 14 September, 2022

Page: [1482 - 1501] Pages: 20

DOI: 10.2174/0929867329666220618162303

Price: $65

Open Access Journals Promotions 2
conference banner
Abstract

Tyrosine kinase inhibitors (TKIs) are effective drug molecules for the treatment of various cancers. Nanomedicinal interventions and approaches may not only provide carrying capacities for TKIs but also potentially target tumor-specific environments and even cellular compartments. Nano-inspired drug delivery systems may hence enhance the efficacy of the drugs through enhanced tumour-availability resulting in greater efficacy and decreased side effects. A variety of nanosystems have been developed for the delivery of TKIs for the enhanced treatment of cancers, each with their own preparation methods and physicochemical properties. This review will therefore discuss the applicability of nano-interventions towards combination therapies, dose reduction, and greater potential treatment outcomes. The individual nanosystems have been highlighted with emphasis on the developed systems and their efficacy against various cancer cell lines and models.

Keywords: Tyrosine kinase inhibitors, nanosystems, cancer, cell lines, nanoparticles, nanomicelles.

« Previous Next »
[1]
Crews, K.R.; Hicks, J.K.; Pui, C.H.; Relling, M.V.; Evans, W.E. Pharmacogenomics and individualized medicine: Translating science into practice. Clin. Pharmacol. Ther., 2012, 92(4), 467-475.
[http://dx.doi.org/10.1038/clpt.2012.120] [PMID: 22948889]
[2]
Monte, A.A.; Heard, K.J.; Vasiliou, V. Prediction of drug response and safety in clinical practice. J. Med. Toxicol., 2012, 8(1), 43-51.
[http://dx.doi.org/10.1007/s13181-011-0198-7] [PMID: 22160757]
[3]
Filipski, K.K.; Mechanic, L.E.; Long, R.; Freedman, A.N. Pharmacogenomics in oncology care. Front. Genet., 2014, 5(5), 73.
[PMID: 24782887]
[4]
Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell, 2011, 144(5), 646-674.
[http://dx.doi.org/10.1016/j.cell.2011.02.013] [PMID: 21376230]
[5]
Hanahan, D.; Weinberg, R.A.; Francisco, S. The hallmarks of cancer. Cell, 2000, 100(1), 57-70.
[http://dx.doi.org/10.1016/S0092-8674(00)81683-9] [PMID: 10647931]
[6]
Abotaleb, M.; Samuel, S.M.; Varghese, E.; Varghese, S.; Kubatka, P.; Liskova, A.; Büsselberg, D. Flavonoids in cancer and apoptosis. Cancers (Basel), 2018, 11(1), 28.
[http://dx.doi.org/10.3390/cancers11010028] [PMID: 30597838]
[7]
Kroemer, G.; Pouyssegur, J. Tumor cell metabolism: Cancer’s Achilles’ heel. Cancer Cell, 2008, 13(6), 472-482.
[http://dx.doi.org/10.1016/j.ccr.2008.05.005] [PMID: 18538731]
[8]
Luo, J.; Solimini, N.L.; Elledge, S.J. Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell, 2009, 136(5), 823-837.
[http://dx.doi.org/10.1016/j.cell.2009.02.024] [PMID: 19269363]
[9]
Fenech, M. Chromosomal biomarkers of genomic instability relevant to cancer. Drug Discov. Today, 2002, 7(22), 1128-1137.
[http://dx.doi.org/10.1016/S1359-6446(02)02502-3] [PMID: 12546856]
[10]
Charames, G.S.; Bapat, B. Genomic instability and cancer. Curr. Mol. Med., 2003, 3(7), 589-596.
[http://dx.doi.org/10.2174/1566524033479456] [PMID: 14601634]
[11]
Negrini, S.; Gorgoulis, V.G.; Halazonetis, T.D. Genomic instability--an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol., 2010, 11(3), 220-228.
[http://dx.doi.org/10.1038/nrm2858] [PMID: 20177397]
[12]
Talseth-Palmer, B.A.; Scott, R.J. Genetic variation and its role in malignancy. Int. J. Biomed. Sci., 2011, 7(3), 158-171.
[PMID: 23675233]
[13]
Haradhvala, N.J.; Polak, P.; Stojanov, P.; Covington, K.R.; Shinbrot, E.; Hess, J.M.; Rheinbay, E.; Kim, J.; Maruvka, Y.E.; Braunstein, L.Z.; Kamburov, A.; Hanawalt, P.C.; Wheeler, D.A.; Koren, A.; Lawrence, M.S.; Getz, G. Mutational strand asymmetries in cancer genomes reveal mechanisms of DNA damage and repair. Cell, 2016, 164(3), 538-549.
[http://dx.doi.org/10.1016/j.cell.2015.12.050] [PMID: 26806129]
[14]
de Vries, N.L.; Mahfouz, A.; Koning, F.; de Miranda, N.F.C.C. Unraveling the complexity of the cancer microenvironment with multidimensional genomic and cytometric technologies. Front. Oncol., 2020, 10, 1254.
[http://dx.doi.org/10.3389/fonc.2020.01254] [PMID: 32793500]
[15]
Robinson, D.R.; Wu, Y.M.; Lin, S.F. The protein tyrosine kinase family of the human genome. Oncogene, 2000, 19(49), 5548-5557.
[http://dx.doi.org/10.1038/sj.onc.1203957] [PMID: 11114734]
[16]
Blume-Jensen, P.; Hunter, T. Oncogenic kinase signalling. Nature, 2001, 411(6835), 355-365.
[http://dx.doi.org/10.1038/35077225] [PMID: 11357143]
[17]
Cohen, P. Protein kinases--the major drug targets of the twenty-first century? Nat. Rev. Drug Discov., 2002, 1(4), 309-315.
[http://dx.doi.org/10.1038/nrd773] [PMID: 12120282]
[18]
Gschwind, A.; Fischer, O.M.; Ullrich, A. The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nat. Rev. Cancer, 2004, 4(5), 361-370.
[http://dx.doi.org/10.1038/nrc1360] [PMID: 15122207]
[19]
Chase, A.; Cross, N.C. Signal transduction therapy in haematological malignancies: Identification and targeting of tyrosine kinases. Clin. Sci. (Lond.), 2006, 111(4), 233-249.
[http://dx.doi.org/10.1042/CS20060035] [PMID: 16961463]
[20]
Lemmon, M.A.; Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell, 2010, 141(7), 1117-1134.
[http://dx.doi.org/10.1016/j.cell.2010.06.011] [PMID: 20602996]
[21]
Drake, J.M.; Lee, J.K.; Witte, O.N. Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer. Mol. Cell. Biol., 2014, 34(10), 1722-1732.
[http://dx.doi.org/10.1128/MCB.01592-13] [PMID: 24567371]
[22]
Knösel, T.; Kampmann, E.; Kirchner, T.; Altendorf-Hofmann, A. Tyrosine kinases in soft tissue tumors. Pathologe, 2014, 35(Suppl. 2), 198-201.
[PMID: 25193679]
[23]
Bhullar, K.S.; Lagarón, N.O.; McGowan, E.M.; Parmar, I.; Jha, A.; Hubbard, B.P.; Rupasinghe, H.P.V. Kinase-targeted cancer therapies: Progress, challenges and future directions. Mol. Cancer, 2018, 17(1), 48.
[http://dx.doi.org/10.1186/s12943-018-0804-2] [PMID: 29455673]
[24]
Smidova, V.; Michalek, P.; Goliasova, Z.; Eckschlager, T.; Hodek, P.; Adam, V.; Heger, Z. Nanomedicine of tyrosine kinase inhibitors. Theranostics, 2021, 11(4), 1546-1567.
[http://dx.doi.org/10.7150/thno.48662] [PMID: 33408767]
[25]
Hubbard, S.R.; Till, J.H. Protein tyrosine kinase structure and function. Annu. Rev. Biochem., 2000, 69, 373-398.
[http://dx.doi.org/10.1146/annurev.biochem.69.1.373] [PMID: 10966463]
[26]
Scheijen, B.; Griffin, J.D. Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene, 2002, 21(21), 3314-3333.
[http://dx.doi.org/10.1038/sj.onc.1205317] [PMID: 12032772]
[27]
Tridente, G. Kinases. In: Adverse Events and Oncotargeted Kinase InhibitorsAcademic Press, 2017, pp. 9-56.
[http://dx.doi.org/10.1016/B978-0-12-809400-6.00002-0]
[28]
Siveen, K.S.; Prabhu, K.S.; Achkar, I.W.; Kuttikrishnan, S.; Shyam, S.; Khan, A.Q.; Merhi, M.; Dermime, S.; Uddin, S. Role of non receptor tyrosine kinases in hematological malignances and its targeting by natural products. Mol. Cancer, 2018, 17(1), 31.
[http://dx.doi.org/10.1186/s12943-018-0788-y] [PMID: 29455667]
[29]
Pawson, T. Regulation and targets of receptor tyrosine kinases. Eur. J. Cancer, 2002, 38(Suppl. 5), S3-S10.
[http://dx.doi.org/10.1016/S0959-8049(02)80597-4] [PMID: 12528767]
[30]
Culhane, J.; Li, E. Targeted therapy with tyrosine kinase inhibitors. US Pharm, 2008, 33(10), 3-14.
[31]
Lahiry, P.; Torkamani, A.; Schork, N.J.; Hegele, R.A. Kinase mutations in human disease: Interpreting genotype-phenotype relationships. Nat. Rev. Genet., 2010, 11(1), 60-74.
[http://dx.doi.org/10.1038/nrg2707] [PMID: 20019687]
[32]
Beretta, G.L.; Cassinelli, G.; Pennati, M.; Zuco, V.; Gatti, L. Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents. Eur. J. Med. Chem., 2017, 142, 271-289.
[http://dx.doi.org/10.1016/j.ejmech.2017.07.062] [PMID: 28851502]
[33]
Metibemu, D.S.; Akinloye, O.A.; Akamo, A.J.; Ojo, D.O.; Okeowo, O.T.; Omotuyi, I.O. Exploring receptor tyrosine kinases inhibitors in Cancer treatments. Egypt. J. Med. Hum. Genet., 2019, 20, 35.
[http://dx.doi.org/10.1186/s43042-019-0035-0]
[34]
Qin, S.; Li, A.; Yi, M.; Yu, S.; Zhang, M.; Wu, K. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J. Hematol. Oncol., 2019, 12(1), 27.
[http://dx.doi.org/10.1186/s13045-019-0718-5] [PMID: 30866992]
[35]
Liang, X.; Yang, Q.; Wu, P.; He, C.; Yin, L.; Xu, F.; Yin, Z.; Yue, G.; Zou, Y.; Li, L.; Song, X.; Lv, C.; Zhang, W.; Jing, B. The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015-2020. Bioorg. Chem., 2021, 113, 105011.
[http://dx.doi.org/10.1016/j.bioorg.2021.105011] [PMID: 34091289]
[36]
Al-Obeidi, F.A.; Lam, K.S. Development of inhibitors for protein tyrosine kinases. Oncogene, 2000, 19(49), 5690-5701.
[http://dx.doi.org/10.1038/sj.onc.1203926] [PMID: 11114749]
[37]
Paul, M.K.; Mukhopadhyay, A.K. Tyrosine kinase - Role and significance in Cancer. Int. J. Med. Sci., 2004, 1(2), 101-115.
[http://dx.doi.org/10.7150/ijms.1.101] [PMID: 15912202]
[38]
Wadleigh, M.; DeAngelo, D.J.; Griffin, J.D.; Stone, R.M. After chronic myelogenous leukemia: Tyrosine kinase inhibitors in other hematologic malignancies. Blood, 2005, 105(1), 22-30.
[http://dx.doi.org/10.1182/blood-2003-11-3896] [PMID: 15358622]
[39]
Kosior, K.; Lewandowska-Grygiel, M.; Giannopoulos, K. Tyrosine kinase inhibitors in hematological malignancies. Postepy Hig. Med. Dosw., 2011, 65, 819-828.
[http://dx.doi.org/10.5604/17322693.968778] [PMID: 22173446]
[40]
Rossi, J.F. Targeted therapies in adult b-cell malignancies. BioMed Res. Int., 2015, 2015, 217593.
[http://dx.doi.org/10.1155/2015/217593] [PMID: 26425544]
[41]
Pottier, C.; Fresnais, M.; Gilon, M.; Jérusalem, G.; Longuespée, R.; Sounni, N.E. Tyrosine kinase inhibitors in cancer: Breakthrough and challenges of targeted therapy. Cancers (Basel), 2020, 12(3), 731.
[http://dx.doi.org/10.3390/cancers12030731] [PMID: 32244867]
[42]
Foroughi-Nia, B.; Barar, J.; Memar, M.Y.; Aghanejad, A.; Davaran, S. Progresses in polymeric nanoparticles for delivery of tyrosine kinase inhibitors. Life Sci., 2021, 278, 119642.
[http://dx.doi.org/10.1016/j.lfs.2021.119642] [PMID: 34033837]
[43]
Lu, Y.; Bian, D.; Zhang, X.; Zhang, H.; Zhu, Z. Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer. Mol. Med. Rep., 2021, 23(1), 48.
[44]
Mansoori, B.; Mohammadi, A.; Davudian, S.; Shirjang, S.; Baradaran, B. The different mechanisms of cancer drug resistance: A brief review; Tabriz University of Medical Sciences, 2017, 7, pp. 339-348.
[45]
Da Silva, C.G.; Peters, G.J.; Ossendorp, F.; Cruz, L.J. The potential of multi-compound nanoparticles to bypass drug resistance in cancer. Cancer Chemother. Pharmacol., 2017, 80(5), 881-894.
[http://dx.doi.org/10.1007/s00280-017-3427-1] [PMID: 28887666]
[46]
Russo, E.; Spallarossa, A.; Tasso, B.; Villa, C.; Brullo, C. Nanotechnology of tyrosine kinase inhibitors in cancer therapy: A perspective. Int. J. Mol. Sci., 2021, 22(12), 6538.
[http://dx.doi.org/10.3390/ijms22126538] [PMID: 34207175]
[47]
Jo, D.H.; Kim, J.H.; Lee, T.G.; Kim, J.H. Size, surface charge, and shape determine therapeutic effects of nanoparticles on brain and retinal diseases. Nanomedicine, 2015, 11(7), 1603-1611.
[http://dx.doi.org/10.1016/j.nano.2015.04.015] [PMID: 25989200]
[48]
Ulldemolins, A.; Seras-Franzoso, J.; Andrade, F.; Rafael, D.; Abasolo, I.; Gener, P.; Schwartz, S., Jr. Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics. Cancer Drug Resist., 2021, 4, 44-68.
[49]
Wicki, A.; Witzigmann, D.; Balasubramanian, V.; Huwyler, J. Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications. J. Control. Release, 2015, 200, 138-157.
[http://dx.doi.org/10.1016/j.jconrel.2014.12.030] [PMID: 25545217]
[50]
Boyles, M.; Powell, L.; Kermanizadeh, A.; Johnston, H.J.; Rothen-Rutishauser, B.; Stone, V.; Clift, M.J.D. An overview of nanoparticle biocompatibility for their use in nanomedicine. In: Pharmaceutical Nanotechnology: Innovation and Production: Innovation and Production; Cornier, J.; Owen, A.; Kwade, A.; Van de Voorde, M., Eds.; Wiley-VCH Verlag GmbH & Co. KGaA: USA, 2017; pp. 443-468.
[http://dx.doi.org/10.1002/9783527800681.ch18]
[51]
Pinto, A.C.; Moreira, J.N.; Simões, S. Liposomal imatinib-mitoxantrone combination: Formulation development and therapeutic evaluation in an animal model of prostate cancer. Prostate, 2011, 71(1), 81-90.
[http://dx.doi.org/10.1002/pros.21224] [PMID: 20607721]
[52]
Zhou, X.; Yung, B.; Huang, Y.; Li, H.; Hu, X.; Xiang, G.; Lee, R.J. Novel liposomal gefitinib (L-GEF) formulations. Anticancer Res., 2012, 32(7), 2919-2923.
[PMID: 22753756]
[53]
Nakhaei, P.; Margiana, R.; Bokov, D.O.; Abdelbasset, W.K.; Jadidi Kouhbanani, M.A.; Varma, R.S.; Marofi, F.; Jarahian, M.; Beheshtkhoo, N. Liposomes: Structure, biomedical applications, and stability parameters with emphasis on cholesterol. Front. Bioeng. Biotechnol., 2021, 9, 705886.
[http://dx.doi.org/10.3389/fbioe.2021.705886] [PMID: 34568298]
[54]
Lakkadwala, S.; Singh, J. Co-delivery of doxorubicin and erlotinib through liposomal nanoparticles for glioblastoma tumor regression using an in vitro brain tumor model. Colloids Surf. B Biointerfaces, 2019, 173, 27-35.
[http://dx.doi.org/10.1016/j.colsurfb.2018.09.047] [PMID: 30261346]
[55]
Çoban, Ö.; Değim, Z.; Yılmaz, Ş.; Altıntaş, L.; Arsoy, T.; Sözmen, M. Efficacy of targeted liposomes and nanocochleates containing imatinib plus dexketoprofen against fibrosarcoma. Drug Dev. Res., 2019, 80(5), 556-565.
[PMID: 30901500]
[56]
Hu, Y.; Zhang, J.; Hu, H.; Xu, S.; Xu, L.; Chen, E. Gefitinib encapsulation based on nano-liposomes for enhancing the curative effect of lung cancer. Cell Cycle, 2020, 19(24), 3581-3594.
[http://dx.doi.org/10.1080/15384101.2020.1852756] [PMID: 33300430]
[57]
Kallus, S.; Englinger, B.; Senkiv, J.; Laemmerer, A.; Heffeter, P.; Berger, W.; Kowol, C.R.; Keppler, B.K. Nanoformulations of anticancer FGFR inhibitors with improved therapeutic index. Nanomedicine, 2018, 14(8), 2632-2643.
[http://dx.doi.org/10.1016/j.nano.2018.08.001] [PMID: 30121385]
[58]
Zhou, X.; Tao, H.; Shi, K.H. Development of a nanoliposomal formulation of erlotinib for lung cancer and in vitro/in vivo antitumoral evaluation. Drug Des. Devel. Ther., 2017, 12, 1-8.
[http://dx.doi.org/10.2147/DDDT.S146925] [PMID: 29296076]
[59]
Ye, H.; Zhou, L.; Jin, H.; Chen, Y.; Cheng, D.; Jian, Y. Sorafenib-loaded long-circulating nanoliposomes for liver cancer therapy. Hindawi BioMed Res. Int., 2020, 2020, 1351046.
[http://dx.doi.org/10.1155/2020/1351046]
[60]
Vaishya, R.D.; Khurana, V.; Patel, S.; Mitra, A.K. Controlled ocular drug delivery with nanomicelles. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2014, 6(5), 422-437.
[http://dx.doi.org/10.1002/wnan.1272] [PMID: 24888969]
[61]
Wang, H.; Li, F.; Du, C.; Wang, H.; Mahato, R.I.; Huang, Y. Doxorubicin and lapatinib combination nanomedicine for treating resistant breast cancer. Mol. Pharm., 2014, 11(8), 2600-2611.
[http://dx.doi.org/10.1021/mp400687w] [PMID: 24405470]
[62]
Yang, Q.; Moulder K, R.; Cohen, M.S.; Cai, S.; Forrest, L.M. Cabozantinib loaded DSPE-PEG2000 micelles as delivery system: Formulation, characterization and cytotoxicity evaluation. BAOJ Pharm. Sci., 2015, 1, 1.
[http://dx.doi.org/10.24947/2380-5552/1/1/00101] [PMID: 25688382]
[63]
Tesan, F.; Cerqueira-Coutinho, C.; Salgueiro, J.; de Souza Albernaz, M.; Pinto, S.R.; Dos Reis, S.S.R.; Bernardes, E.S.; Chiapetta, D.; Zubillaga, M.; Santos-Oliveira, R. Characterization and biodistribution of bevacizumab TPGS-based nanomicelles: Preliminary studies. J. Drug Deliv. Sci. Technol., 2016, 36, 95-98.
[http://dx.doi.org/10.1016/j.jddst.2016.09.011]
[64]
Zhang, S.; Zhao, L.; Peng, X.; Sun, Q.; Liao, X.; Gan, N.; Zhao, G.; Li, H. Self-assembled phospholipid-based mixed micelles for improving the solubility, bioavailability and anticancer activity of lenvatinib. Colloids Surf. B Biointerfaces, 2021, 201, 111644.
[http://dx.doi.org/10.1016/j.colsurfb.2021.111644] [PMID: 33639512]
[65]
Bahman, F.; Pittalà, V.; Haider, M.; Greish, K. Enhanced anticancer activity of nanoformulation of dasatinib against triple-negative breast cancer. J. Pers. Med., 2021, 11(6), 559.
[http://dx.doi.org/10.3390/jpm11060559] [PMID: 34204015]
[66]
Delmarre, D.; Tatton, N.; Krause-Elsmore, S. Formulation of hydrophobic drug into cochleate delivery vehicles: A simplified protocol and formulation kit. Drug Deliv. Technol., 2004, 1, 64-69.
[67]
Çoban, Ö.; Değim, Z. Development of nanocochleates containing erlotinib hcl and dexketoprofen trometamol and evaluation of in vitro characteristic properties. Turk. J. Pharm. Sci., 2018, 15(1), 16-21.
[PMID: 32454635]
[68]
Junghanns, J.U.; Müller, R.H. Nanocrystal technology, drug delivery and clinical applications. Int. J. Nanomedicine, 2008, 3(3), 295-309.
[PMID: 18990939]
[69]
Thakkar, S.; Sharma, D.; Misra, M. Comparative evaluation of electrospraying and lyophilization techniques on solid state properties of Erlotinib nanocrystals: Assessment of in-vitro cytotoxicity. Eur. J. Pharm. Sci., 2018, 111, 257-269.
[http://dx.doi.org/10.1016/j.ejps.2017.10.008] [PMID: 28989102]
[70]
Zare, E.N.; Padil, V.V.T.; Mokhtari, B.; Venkateshaiah, A.; Wacławek, S.; Černík, M.; Tay, F.R.; Varma, R.S.; Makvandi, P. Advances in biogenically synthesized shaped metal- and carbon-based nanoarchitectures and their medicinal applications. Adv. Colloid Interface Sci., 2020, 283, 102236.
[http://dx.doi.org/10.1016/j.cis.2020.102236] [PMID: 32829011]
[71]
Shu, M.; Gao, F.; Yu, C.; Zeng, M.; He, G.; Wu, Y.; Su, Y.; Hu, N.; Zhou, Z.; Yang, Z.; Xu, L. Dual -targeted therapy in HER2-positive breast cancer cells with the combination of carbon dots/HER3 siRNA and trastuzumab. Nanotechnology, 2020, 335102, 12.
[72]
Mohapatra, A.; Uthaman, S.; Park, I-K. Chapter 10 - Polyethylene Glycol Nanoparticles as Promising Tools for Anticancer Therapeutics. In: Polymeric Nanoparticles as a Promising Tool for Anti-cancer Therapeutics; Kesharwani, P.; Paknikar, K.M.; Gajbhiye, V., Eds.; Academic Press, USA, 2019; pp. 205-231.
[http://dx.doi.org/10.1016/B978-0-12-816963-6.00010-8]
[73]
Zhou, X.; He, X.; Shi, K.; Yuan, L.; Yang, Y.; Liu, Q.; Ming, Y.; Yi, C.; Qian, Z. Injectable thermosensitive hydrogel containing erlotinib-loaded hollow mesoporous silica nanoparticles as a localized drug delivery system for NSCLC therapy. Adv. Sci. (Weinh.), 2020, 7(23), 2001442.
[http://dx.doi.org/10.1002/advs.202001442] [PMID: 33304746]
[74]
Singh, N.A.; Pandey, K. Chapter 13 - Advanced drug delivery systems in kidney cancer. In: Advanced Drug Delivery Systems in the Management of Cancer; Dua, K.; Mehta, M.; de Jesus, T.; Pinto, A.; Pont, L.G.; Williams, K.A.; Rathbone, M.J. Academic Press, USA, 2021; pp. 155-181.
[75]
Chiang, C-S.; Hu, S-H.; Liao, B-J.; Chang, Y-C.; Chen, S-Y. Enhancement of cancer therapy efficacy by trastuzumab-conjugated and pH-sensitive nanocapsules with the simultaneous encapsulation of hydrophilic and hydrophobic compounds. Nanomedicine, 2014, 10(1), 99-107.
[http://dx.doi.org/10.1016/j.nano.2013.07.009] [PMID: 23891983]
[76]
Sherje, A.P.; Dravyakar, B.R.; Kadam, D.; Jadhav, M. Cyclodextrin-based nanosponges: A critical review. Carbohydr. Polym., 2017, 173, 37-49.
[http://dx.doi.org/10.1016/j.carbpol.2017.05.086] [PMID: 28732878]
[77]
Pandey, P.; Purohit, D.; Dureja, H. Nanosponges -A promising novel drug delivery system. Recent Pat. Nanotechnol., 2018, 12(3), 180-191.
[http://dx.doi.org/10.2174/1872210512666180925102842] [PMID: 30251614]
[78]
Dora, C.P.; Trotta, F.; Kushwah, V.; Devasari, N.; Singh, C.; Suresh, S.; Jain, S. Potential of erlotinib cyclodextrin nanosponge complex to enhance solubility, dissolution rate, in vitro cytotoxicity and oral bioavailability. Carbohydr. Polym., 2016, 137, 339-349.
[http://dx.doi.org/10.1016/j.carbpol.2015.10.080] [PMID: 26686138]
[79]
Momin, M.M.; Zaheer, Z.; Zainuddin, R.; Sangshetti, J.N. Extended release delivery of erlotinib glutathione nanosponge for targeting lung cancer. Artif. Cells Nanomed. Biotechnol., 2018, 46(5), 1064-1075.
[http://dx.doi.org/10.1080/21691401.2017.1360324] [PMID: 28758795]
[80]
Ahmed, M.M.; Fatima, F.; Anwer, K.; Ansari, M.J.; Das, S.S.; Alshahrani, S.M. Development and characterization of ethyl cellulose nanosponges for sustained release of brigatinib for the treatment of non-small cell lung cancer. J. Polym. Eng., 2020, 40(10), 823-832.
[http://dx.doi.org/10.1515/polyeng-2019-0365]
[81]
Obeas, L.K.; Ghalib, A.K.; Alsultan, G.A.K.; Asikin-Mijan, N.; Yunus, R. A review on nanorods - an overview from synthesis to emerging, device applications and toxicity. Orient. J. Chem., 2021, 37(2), 370201.
[http://dx.doi.org/10.13005/ojc/370201]
[82]
Liu, J.; Abshire, C.; Carry, C.; Sholl, A.B.; Mandava, S.H.; Datta, A.; Ranjan, M.; Callaghan, C.; Peralta, D.V.; Williams, K.S.; Lai, W.R.; Abdel-Mageed, A.B.; Tarr, M.; Lee, B.R. Nanotechnology combined therapy: Tyrosine kinase-bound gold nanorod and laser thermal ablation produce a synergistic higher treatment response of renal cell carcinoma in a murine model. BJU Int., 2017, 119(2), 342-348.
[http://dx.doi.org/10.1111/bju.13590] [PMID: 27431021]
[83]
Escobar-Chávez, J.J.; Rodríguez-Cruz, I.M.; Domínguez-Delgado, C.L. Nanocarrier Systems for Transdermal Drug Delivery, Recent Advances in Novel Drug Carrier Systems, 2012,
[http://dx.doi.org/10.5772/50314]
[84]
Karade, V.C.; Sharma, A.; Dhavale, R.P.; Dhavale, R.P.; Shingte, S.R.; Patil, P.S.; Kim, J.H.; Zahn, D.R.T.; Chougale, A.D.; Salvan, G.; Patil, P.B. APTES monolayer coverage on self-assembled magnetic nanospheres for controlled release of anticancer drug Nintedanib. Sci. Rep., 2021, 11(1), 5674.
[http://dx.doi.org/10.1038/s41598-021-84770-0] [PMID: 33707549]
[85]
Maruyama, T. Chapter 6 - Carbon nanotubes. In: Micro and Nano Technologies, Handbook of Carbon-Based Nanomaterials; Thomas, S.; Sarathchandran, C.; Ilangovan, S.A.; Moreno-Piraján, J.C., Eds.; Elsevier , 2021, pp. 299-319.
[http://dx.doi.org/10.1016/B978-0-12-821996-6.00009-9]
[86]
Oraki Kohshour, M.; Mirzaie, S.; Zeinali, M.; Amin, M.; Said Hakhamaneshi, M.; Jalili, A.; Mosaveri, N.; Jamalan, M. Ablation of breast cancer cells using trastuzumab-functionalized multi-walled carbon nanotubes and trastuzumab-diphtheria toxin conjugate. Chem. Biol. Drug Des., 2014, 83(3), 259-265.
[http://dx.doi.org/10.1111/cbdd.12244] [PMID: 24118702]
[87]
Khan, I.; Saeed, K.; Khan, I. Nanoparticles: Properties, applications and toxicities. Arab. J. Chem., 2019, 908-931.
[http://dx.doi.org/10.1016/j.arabjc.2017.05.011]
[88]
Kydd, J.; Jadia, R.; Rai, P. Co-administered polymeric nano-antidotes for improved photo-triggered response in glioblastoma. Pharmaceutics, 2018, 10(4), 226.
[http://dx.doi.org/10.3390/pharmaceutics10040226] [PMID: 30423822]
[89]
Wang, J.; Su, G.; Yin, X.; Luo, J.; Gu, R.; Wang, S.; Feng, J.; Chen, B. Non-small cell lung cancer-targeted, redox-sensitive lipid-polymer hybrid nanoparticles for the delivery of a second-generation irreversible epidermal growth factor inhibitor-Afatinib: In vitro and in vivo evaluation. Biomed. Pharmacother., 2019, 120, 109493.
[http://dx.doi.org/10.1016/j.biopha.2019.109493] [PMID: 31586902]
[90]
Vaidya, B.; Parvathaneni, V.; Kulkarni, N.S.; Shukla, S.K.; Damon, J.K.; Sarode, A.; Kanabar, D.; Garcia, J.V.; Mitragotri, S.; Muth, A.; Gupta, V. Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer. Int. J. Biol. Macromol., 2019, 122, 338-347.
[http://dx.doi.org/10.1016/j.ijbiomac.2018.10.181] [PMID: 30401652]
[91]
Zhou, C.; Shi, Q.; Liu, J.; Huang, S.; Yang, C.; Xiong, B. Effect of inhibiting tumor angiogenesis after embolization in the treatment of hcc with apatinib-loaded p(N-isopropyl-acrylamide-co-butyl methyl acrylate) temperature-sensitive nanogel. J. Hepatocell. Carcinoma, 2020, 7, 447-456.
[http://dx.doi.org/10.2147/JHC.S282209] [PMID: 33409168]
[92]
Zhang, H.; Cui, W.; Qu, X.; Wu, H.; Qu, L.; Zhang, X.; Mäkilä, E.; Salonen, J.; Zhu, Y.; Yang, Z.; Chen, D.; Santos, H.A.; Hai, M.; Weitz, D.A. Photothermal-responsive nanosized hybrid polymersome as versatile therapeutics codelivery nanovehicle for effective tumor suppression. Proc. Natl. Acad. Sci. USA, 2019, 116(16), 7744-7749.
[http://dx.doi.org/10.1073/pnas.1817251116] [PMID: 30926671]
[93]
Li, X.; Wang, L.; Wang, L.; Yu, J.; Lu, G.; Zhao, W.; Miao, C.; Zou, C.; Wu, J. Overcoming therapeutic failure in osteosarcoma via Apatinib-encapsulated hydrophobic poly(ester amide) nanoparticles. Biomater. Sci., 2020, 8(21), 5888-5899.
[http://dx.doi.org/10.1039/D0BM01296C] [PMID: 33001086]

Rights & Permissions Print Cite
Article Metrics
54
2
Wayfinder Image
Open Access Journals Promotions
World Antimicrobial Awareness Week
© 2024 Bentham Science Publishers | Privacy Policy